<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03335371</url>
  </required_header>
  <id_info>
    <org_study_id>TTP399-203</org_study_id>
    <secondary_id>JDRF#2-IND-2018-500</secondary_id>
    <nct_id>NCT03335371</nct_id>
  </id_info>
  <brief_title>Evaluation of TTP399 in Patients With Type 1 Diabetes</brief_title>
  <acronym>SimpliciT1</acronym>
  <official_title>A Multi-Center, Randomized, Double-Blind, Parallel-Group, Multiple-Dose, Adaptive Study Assessing the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of TTP399 in With Adult Patients Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>vTv Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>vTv Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of TTP399 in Type 1
      diabetics. This study will be in 2 phases: phase 1 will evaluate the safety of different
      TTP399 dosage regimens over 1 week of daily dosing. Phase 2 will evaluate the safety and
      efficacy of a TTP399 dosing regimen over 12 weeks of daily dosing.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 25, 2017</start_date>
  <completion_date type="Actual">January 6, 2020</completion_date>
  <primary_completion_date type="Actual">December 20, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c from baseline at 12 weeks</measure>
    <time_frame>Day 1 to Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Week -2 to Week 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in target glycemic range (70-180 mg/dL)</measure>
    <time_frame>Week -2 to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in hyperglycemic range (Level 1 &gt; 180 mg/dL, Level 2 (&gt;250 mg/dL)</measure>
    <time_frame>Week -2 to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in hypoglycemic range (Level 1 &lt; 70 mg/dL, Level 2 &lt; 54 mg/dL)</measure>
    <time_frame>Week -2 to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total daily insulin dose</measure>
    <time_frame>Week -2 to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of meal time bolus insulin</measure>
    <time_frame>Week -2 to Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">115</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>TTP399 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTP399</intervention_name>
    <description>Phase 1: Participants will receive TTP399 administered orally up to 1200 mg taken once daily for 7 days</description>
    <arm_group_label>TTP399 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTP399</intervention_name>
    <description>Phase 2: Participants will receive TTP399 administered orally 800 mg taken once daily for 12 weeks</description>
    <arm_group_label>TTP399 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Phase 2: Participants will receive Placebo oral tablets for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  People diagnosed with T1DM, confirmed diagnosis prior to 40 years of age and a
             diagnosed for minimum of 1 year.

          -  Type 1 diabetics using either continuous subcutaneous insulin infusion (with lispro or
             aspart) or multiple daily doses of insulin

          -  Willing to use adequate contraception

          -  No major surgeries or significant injuries within the past year and without an active
             infection.

        Exclusion Criteria:

          -  Diagnosis of T2DM, severely uncontrolled T1DM, maturity-onset diabetes of the young,
             insulin-requiring T2DM, other unusual or rare forms of diabetes mellitus, diabetes
             resulting from a secondary disease

          -  Receipt of an investigational product within 30 days of the Screening Visit or any
             therapeutic protein or antibody within 90 days prior to Screening Visit or any
             previous treatment with TTP399.

          -  Living in the same household or related to another participant in this study.

          -  Two severe episodes of hypoglycemia that required assistance by a third party within 3
             months of Screening Visit

          -  Use of antidiabetic medications other than insulin 3 months prior to Screening Visit,
             systemic corticosteroids 1 month prior to Screening Visit, weight loss medication 2
             weeks prior to Screening Visit, and antipsychotic medications 3 months prior to
             Screening Visit.

          -  Participation in any formal weight loss program or contemplating such therapy during
             the trial.

          -  Recent history of use of non-prescribed controlled substances or illicit drugs.

          -  Current alcoholism or a history of excessive alcohol consumption within 2 years prior
             to screening

          -  History or presence of symptomatic autonomic neuropathy or chronic gastrointestinal
             disease.

          -  Personal history of long QT syndrome.

          -  Blood donation of approximately 1 pint (500 mL) within 8 weeks before Screening Visit

          -  History of hemolytic anemia or chronic transfusion requirement.

          -  History of cancer, other than non-melanoma skin cancer or uterine cervical cancer that
             required therapy in the past 5 years.

          -  Breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carmen Valcarce, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>vTv Therapeutics, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC Westside Center for Diabetes</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMCR Institute</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Barbara Davis Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Diabetes Associate</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Diabetes Center</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iowa Diabetes Research</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountain Diabetes and Endocrine Center</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Diabetes Care Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Diabetes Research Clinic</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes &amp; Endocrinology Consultants</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intend Research</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas Diabetes Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medicine Diabetes Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 31, 2017</study_first_submitted>
  <study_first_submitted_qc>November 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

